Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results

被引：0

作者：

Gutierrez, Martin

Spreafico, Anna

Wang, Ding

Golan, Talia

Renouf, Daniel

Voskoboynik, Mark

Chatterjee, Manash Shankar

Kapadia, Kishan J.

Liu, Qi

Kovvali, Gopala

Suttner, Leah

Pang, Ling

Chen, Mei

Tolcher, Anthony W.

机构：

[1] Hackensack Univ Med Ctr, Hackensack, NJ USA

[2] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Merck Co Inc, Kenilworth, NJ USA

[4] Henry Ford Hosp, Detroit, MI USA

[5] Tel Aviv Univ, Sheba Med Ctr, Ramat Gan, Israel

[6] BC Cancer, Vancouver, BC, Canada

[7] Univ British Columbia, Vancouver, BC, Canada

[8] Monash Univ, Cent Clin Sch, Alfred Hlth, Melbourne, Vic, Australia

[9] Merck Co Inc, Kenilworth, NJ USA

[10] South Texas Accelerated Res Therapeut, San Antonio, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2505

引用

页数：1

共 50 条

[31] A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors [J].

Deva, Sanjeev ;

Zhou, Caicun ;

Bishnoi, Sarwan K. ;

Lau, Peter Kar Han ;

Tran, Ben ;

Ba, Yi ;

Galsky, Matt D. ;

Wang, Yongsheng ;

Zhang, Yanqiao ;

Luo, Suxia ;

Chang, Victoria ;

Yu, Cunjing ;

Zhang, Teresa ;

Zhang, Heather ;

Ma, Jiafang ;

Naicker, Kirsha May ;

Yap, Timothy A. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[32] A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours [J].

Teneggi, V. ;

Ng, M. ;

Tan, D. S. ;

Subbiah, V. ;

Weekes, C. ;

Diermayr, V. ;

Ethirajulu, K. ;

Yeo, P. ;

Chen, D. ;

Gan, S. ;

Blanchard, S. ;

Nellore, R. ;

Lee, M. A. ;

Hill, J. ;

Virshup, D. ;

Madan, B. ;

Matter, A. .

ANNALS OF ONCOLOGY, 2016, 27

[33] First-in-human dose escalation study of oral ONC201 in advanced solid tumors. [J].

Stein, Mark N. ;

Mayer, Tina M. ;

Moss, Rebecca Anne ;

Silk, Ann W. ;

Chan, Nancy ;

Haffty, Bruce George ;

DiPaola, Robert S. ;

Beckett, Yasmeen ;

Bentlyewski, Edward ;

Zheng, Ling ;

Fang, Bruno ;

Allen, Joshua ;

Mehnert, Janice M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[34] First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors [J].

Babu, S. ;

Kondo, S. ;

Ammakkanavar, N. ;

Spira, A. I. ;

Perets, R. ;

Doi, T. ;

Bar, J. ;

Vandross, A. ;

Sommerhalder, D. ;

Nikolic, V. ;

Tribouley, C. ;

Atluri, H. ;

Hong, J. ;

Paustian, A. ;

Leibman, R. ;

Powderly, J. .

ANNALS OF ONCOLOGY, 2023, 34 :S647-S648

[35] First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer [J].

Niu, J. ;

Maurice-Dror, C. ;

Lee, D. H. ;

Kim, D. -W. ;

Nagrial, A. ;

Voskoboynik, M. ;

Chung, H. C. ;

Mileham, K. ;

Vaishampayan, U. ;

Rasco, D. ;

Golan, T. ;

Bauer, T. M. ;

Jimeno, A. ;

Chung, V. ;

Chartash, E. ;

Lala, M. ;

Chen, Q. ;

Healy, J. A. ;

Ahn, M. -J. .

ANNALS OF ONCOLOGY, 2022, 33 (02) :169-180

[36] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors [J].

Sommerhalder, David ;

Hamilton, Erika P. ;

Mukohara, Toru ;

Yonemori, Kan ;

Mita, Monica M. ;

Yamashita, Toshinari ;

Zheng, Jenny ;

Liu, Li ;

Maity, Arnab K. ;

Mishra, Natasha Homji ;

Bogg, Orlaith ;

Li, Meng ;

LoRusso, Patricia .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[37] Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors [J].

Sharma, Sunil ;

Starodub, Alexander ;

Xu, Nong ;

Chaudhry, Arvind ;

Sun, Meili ;

Pelster, Meredith ;

Fu, Yinjia ;

Zhang, Xinyu ;

Huang, Zhao ;

Liu, Wenyu ;

Hsu, Karl .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[38] Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors. [J].

Fedyanin, Mikhail ;

Tryakin, Alexey ;

Lisyanskaya, Alla Sergeevna ;

Solovyeva, Ekaterina ;

Fadeeva, Natalia ;

Gladkov, Oleg ;

Moiseyenko, Vladimir ;

Cheporov, Sergey, V ;

Shpigotskaya, Polina ;

Purmal, Andrei ;

Miller, Langdon L. ;

Leonov, Andrey ;

Zakurdaeva, Kristina ;

Gurova, Katerina ;

Gudkov, Andrei ;

Tjulandin, Sergei .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[39] Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors. [J].

Powderly, John ;

Shimizu, Toshio ;

LoRusso, Patricia ;

Razak, Albiruni ;

Miller, Kathy ;

Balar, Arjun ;

Bruix, Jordi ;

Michel, Loren ;

Blaney, Martha ;

Guan, Xiaowen ;

Lacy, Susan ;

Lally, Satwant ;

Lambert, Stacie ;

Leibman, Rachel ;

Vosganian, Gregory ;

Golan, Talia ;

Tolcher, Anthony .

CANCER RESEARCH, 2021, 81 (13)

[40] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors (vol 14, 1376551, 2024) [J].

Shimizu, Toshio ;

Powderly, John ;

Abdul Razak, Albiruni ;

Lorusso, Patricia ;

Miller, Kathy D. ;

Kao, Steven ;

Kongpachith, Sarah ;

Tribouley, Catherine ;

Graham, Michelle ;

Stoll, Brian ;

Patel, Maulik ;

Sahtout, Mohammad ;

Blaney, Martha ;

Leibman, Rachel ;

Golan, Talia ;

Tolcher, Anthony .

FRONTIERS IN ONCOLOGY, 2025, 14

← 1 2 3 4 5 →